CADTH | Search

Current Filters

Showing 81 - 90 results of 3579

Rivaroxaban (Xarelto) (Last Updated: May 6, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Xarelto
Manufacturer:
Bayer Inc.
Submission Type:
Initial
Indications:

Thromboembolic events (venous), pulmonary embolism

Rivaroxaban (Xarelto) (Last Updated: Mar 18, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Xarelto
Manufacturer:
Bayer Inc.
Submission Type:
Request For Advice
Indications:

stroke prevention in patients with atrial fibrillation.

Dabigatran etexilate (Pradaxa) (Last Updated: Mar 18, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Pradaxa
Manufacturer:
Boehringer Ingelheim (Canada) Ltd
Submission Type:
Request For Advice
Indications:

Atrial fibrillation prevention of stroke and systemic embolism

Mirabegron (Myrbetriq) (Last Updated: Mar 8, 2013)

Project Line:
Reimbursement Review
Project Status:
Withdrawn
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Myrbetriq
Manufacturer:
Astellas Pharma Canada, Inc.
Submission Type:
Initial
Indications:

Bladder, Overactive

Azilsartan medoxomil + chlorthalidone (Edarbyclor) (Last Updated: Mar 8, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Edarbyclor
Manufacturer:
Takeda Canada Inc.
Submission Type:
Initial
Indications:

Hypertension, essential

Azilsartan medoxomil (Edarbi) (Last Updated: Mar 8, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Edarbi
Manufacturer:
Takeda Canada Inc.
Submission Type:
Initial
Indications:

Hypertension, essential

Zolpidem tartrate (Sublinox) (Last Updated: Mar 7, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Sublinox
Manufacturer:
Meda Valeant Pharma Canada Inc.
Submission Type:
Initial
Indications:

Insomnia, short-term treatment

Boceprevir (Victrelis) (Last Updated: Feb 19, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Victrelis
Manufacturer:
Merck Canada Inc.
Submission Type:
Request For Advice
Indications:

Hepatitis C infection, chronic

Telaprevir (Incivek) (Last Updated: Feb 19, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Incivek
Manufacturer:
Vertex Pharmaceuticals Canada Inc.
Submission Type:
Request For Advice
Indications:

Hepatitis C infection, chronic

Perampanel (Fycompa) (Last Updated: Mar 8, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Fycompa
Manufacturer:
Eisai Ltd.
Submission Type:
Initial
Indications:

Epilepsy, partial onset seizures

Download results as CSV